Literature DB >> 28275952

The Anticonvulsant Screening Program of the National Institute of Neurological Disorders and Stroke, NIH: History and Contributions to Clinical Care in the Twentieth Century and Beyond.

Roger J Porter1,2,3, Harvey J Kupferberg4.   

Abstract

The anticonvulsant screening program (ASP) of the national institute of neurological disorders and stroke (NINDS), National Institutes of Health has made substantial contributions to the drug armamentarium of the clinical neurologist. This program, originally a part of the overall Drug Development Program of the Epilepsy Branch, has been fortunate to have talented leadership, both at NINDS in Maryland and at the major contract site, the University of Utah-over a remarkable period of more than 40 years. Future discoveries by the ASP (now renamed the Epilepsy Therapy Screening) can be expected to make additional contributions to improving the health of persons with epilepsy.

Entities:  

Keywords:  Anti-seizure; Anticonvulsant; Epilepsy; Screening; Seizure

Mesh:

Substances:

Year:  2017        PMID: 28275952     DOI: 10.1007/s11064-017-2215-y

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  9 in total

1.  Comparative assays of antiepileptic drugs in mice and rats.

Authors:  E A SWINYARD; W C BROWN; L S GOODMAN
Journal:  J Pharmacol Exp Ther       Date:  1952-11       Impact factor: 4.030

2.  The petit mal epilepsies; their treatment with tridione.

Authors:  W G LENNOX
Journal:  J Am Med Assoc       Date:  1945-12-15

3.  EXPERIMENTAL DETERMINATION OF THE ANTICONVULSANT PROPERTIES OF SOME PHENYL DERIVATIVES.

Authors:  T J Putnam; H H Merritt
Journal:  Science       Date:  1937-05-28       Impact factor: 47.728

Review 4.  Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma.

Authors:  Wolfgang Löscher; Dieter Schmidt
Journal:  Epilepsia       Date:  2011-03-22       Impact factor: 5.864

Review 5.  Medicines for the mind: policy-based "pull" incentives for creating breakthrough CNS drugs.

Authors:  Dennis W Choi; Robert Armitage; Linda S Brady; Timothy Coetzee; William Fisher; Steven Hyman; Atul Pande; Steven Paul; William Potter; Benjamin Roin; Todd Sherer
Journal:  Neuron       Date:  2014-11-05       Impact factor: 17.173

6.  Mechanisms of action of anti-seizure drugs and the anticonvulsant screening program of the National Institute of Neurological Disorders and Stroke.

Authors:  Roger J Porter; Harvey J Kupferberg; Bettie Jean Hessie
Journal:  Int J Clin Pharmacol Ther       Date:  2015-01       Impact factor: 1.366

7.  Antiepileptic Drug Development Program.

Authors:  R J Porter; J J Cereghino; G D Gladding; B J Hessie; H J Kupferberg; B Scoville; B G White
Journal:  Cleve Clin Q       Date:  1984

8.  Carbamazepine for epilepsy. A controlled prospective evaluation.

Authors:  J J Cereghino; J T Brock; J C Van Meter; J K Penry; L D Smith; B G White
Journal:  Neurology       Date:  1974-05       Impact factor: 9.910

9.  Diagnostic and therapeutic reevaluation of patients with intractable epilepsy.

Authors:  R J Porter; J K Penry; J R Lacy
Journal:  Neurology       Date:  1977-11       Impact factor: 9.910

  9 in total
  5 in total

Review 1.  Animal Models of Seizures and Epilepsy: Past, Present, and Future Role for the Discovery of Antiseizure Drugs.

Authors:  Wolfgang Löscher
Journal:  Neurochem Res       Date:  2017-03-13       Impact factor: 3.996

Review 2.  Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options.

Authors:  Wolfgang Löscher; Heidrun Potschka; Sanjay M Sisodiya; Annamaria Vezzani
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

3.  Interactions among Lacosamide and Second-Generation Antiepileptic Drugs in the Tonic-Clonic Seizure Model in Mice.

Authors:  Katarzyna Załuska-Ogryzek; Paweł Marzęda; Paula Wróblewska-Łuczka; Magdalena Florek-Łuszczki; Zbigniew Plewa; Hubert Bojar; Dorota Zolkowska; Jarogniew J Łuszczki
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

4.  Anticonvulsant Effectiveness and Neurotoxicity Profile of 4-butyl-5-[(4-chloro-2-methylphenoxy)methyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione (TPL-16) in Mice.

Authors:  Magdalena Drabik; Mariusz Głuszak; Paula Wróblewska-Łuczka; Zbigniew Plewa; Marek Jankiewicz; Justyna Kozińska; Magdalena Florek-Łuszczki; Tomasz Plech; Jarogniew J Łuszczki
Journal:  Neurochem Res       Date:  2020-11-18       Impact factor: 3.996

Review 5.  The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond.

Authors:  Wolfgang Löscher; Pavel Klein
Journal:  CNS Drugs       Date:  2021-06-18       Impact factor: 5.749

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.